Opendata, web and dolomites

CandidaHunter SIGNED

A Nanotechnology Based Blood Culture Medium to Detect Invasive Candida in Bloodstream

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CandidaHunter project word cloud

Explore the words cloud of the CandidaHunter project. It provides you a very rough idea of what is the project "CandidaHunter" about.

considering    company    countries    period    expertise    fast    believes    distributed    hospital    therapy    rising    infections    sensitivity    bloodstream    incidence    detection    aging    infection    biotechnology    candidiasis    80    golden    always    severe    population    demand    therapeutic    offers    medium    treatment    internal    roughly    culture    diagnosis    newer    itself    40    kits    million    commercialized    monitoring    2002    drug    37    delayed    medical    intensive    solution    disease    opportunity    innovation    assay    shows    matriks    4th    technologies    solutions    world    benefit    extensive    reg    biotek    owing    introduces    mortality    50    shorter    detect    gold    standard    leverage    market    rate    candidahunter    sought    days    blood    people    sme    nanotechnology    hours    immunogenicity    time    latest    media    advancements    diagnostic    tests    share    name    antifungal    commercializing    undiagnosed    conventional    organs    global    24    easily    fungal   

Project "CandidaHunter" data sheet

The following table provides information about the project.

Coordinator
MATRIKS BIYOTEKNOLOJI SANAYI VE TICARET LIMITED SIRKETI 

Organization address
address: GAZI UNIVERSITESI GOLBASI YERLESKESI TEKNOPLAZA BINASI B BLOK ZEMIN KAT BZ 17
city: GOLBASI ANKARA
postcode: 6830
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MATRIKS BIYOTEKNOLOJI SANAYI VE TICARET LIMITED SIRKETI TR (GOLBASI ANKARA) coordinator 50˙000.00

Map

 Project objective

CandidaHunter is the latest diagnostic innovation of Matriks Biotek®, owing to its years of expertise on medical biotechnology. The company has already developed and commercialized many diagnostic kits distributed over 37 countries around the world. This time Matriks Biotek targets Candidiasis, a fungal infection affecting roughly a million of people each year, making it the 4th leading cause of hospital infections. The mortality rate of 40% associated with the disease shows there is still much to improve in antifungal therapy.

The Challenge The most crucial need in Candidiasis treatment is fast diagnosis. Blood culture is the gold standard assay for Candidiasis diagnosis but can only detect 50% of the cases within 3 to 5 days. Delayed treatment and undiagnosed cases lead to dissemination of the disease and cause severe infections in internal organs.

Our Solution Matriks Biotek introduces CandidaHunter as a fast blood culture medium to detect Candidiasis in bloodstream. Enhancing the golden standard with nanotechnology, CandidaHunter offers an increased detection sensitivity of 80% and a much shorter diagnosis period of 24 hours.

The Opportunity Factors like high incidence of infections, rising demand for fast diagnostic tests, aging population as well as advancements in medical technology always make newer and better solutions highly sought after. Considering its unique features, Matriks Biotek believes CandidaHunter will easily make a name for itself all around the world. Culture based technologies have the largest share in the diagnostic market due to the extensive usage of conventional blood culture media. By commercializing it on global scale, Matriks Biotek aims to benefit from CandidaHunter with its potential leverage effects and apply its capabilities to a new market.

Matriks Biotek is an R&D intensive SME established in 2002 with a main focus on therapeutic drug monitoring and immunogenicity detection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANDIDAHUNTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANDIDAHUNTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More